Excluding invalid data [Study As­sess­ment]

posted by Ohlbe – France, 2017-10-30 18:03  – Posting: # 17956
Views: 5,500

Hi Helmut,

» What do you think a regulator would prefer?
  1. Excluding the subject and assess BE based on valid data only.
    »
  2. Keep the subject though the reanalysed Cmax in one period is not valid.

Please don't misunderstand what I mean. I'm certainly not pleading to use data which were not demonstrated to be valid during method validation. I would not extrapolate above the ULOQ and I would not analyse a sample beyond its stability period. But let me play the devil's advocate too. Let's imagine your subject had a Cmax at midrange of the calibration curve in Period 1 and is at least 5 x ULOQ in Period 2 (still ULOQ after a 1/5 dilution). Regulators would not be happy with the exclusion of the subject. Which doesn't mean that they would like possibly unreliable data to be used instead: rather that they may reject the study as a whole :-(. Regulators don't wear Armani suits.

OK, we're discussing rather extreme situations. Let's remain optimistic and hope that Anand still has enough plasma for re-analysis, that the analyte is stable, and that the validation of the higher dilution factor will pass :-)

Regards
Ohlbe

Complete thread:

Activity
 Mix view
Bioequivalence and Bioavailability Forum |  Admin contact
19,884 posts in 4,214 threads, 1,365 registered users;
online 14 (0 registered, 14 guests [including 6 identified bots]).
Forum time (Europe/Vienna): 20:41 CEST

Competence, like truth, beauty and contact lenses,
is in the eye of the beholder.    Laurence J. Peter

The BIOEQUIVALENCE / BIOAVAILABILITY FORUM is hosted by
BEBAC Ing. Helmut Schütz
HTML5